Compare Merck & Co., Inc. (MRK) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Merck & Co., Inc. trades at $144.98 (market cap $351.28B), while Vanguard Short Term Corporate Bond ETF trades at $77.27 (market cap $51.90B). The key difference: Merck & Co., Inc. is far larger — about 6.8× Vanguard Short Term Corporate Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| MRK | VCSH | |
|---|---|---|
Market Cap | $351.28B | $51.90B |
Volume | 7,969,665 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $80.20 |
52-Week Low | $82.49 | $77.03 |
Typical Hold Time | 98 Days | 52 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
VCSH trades at $77.285 with minimal daily movement (+0.02%). The technical outlook is bearish with moving averages signaling caution, though oscillators remain neutral. Recent news highlights VCSH's competitive 4.5% dividend yield and low 0.03% expense ratio, positioning it as a stable income alternative to CDs or stable value funds. The fund's short 2.7-year duration minimizes interest rate risk, but credit spreads remain tight, limiting near-term upside potential.
VCSH offers conservative investors higher yields than traditional safe-harbor investments with minimal volatility. The primary risk involves corporate credit exposure during economic downturns, while the main opportunity lies in its attractive risk-adjusted returns for short-term bond allocations. Current market sentiment is neutral with some institutional rotation observed in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
